Form 4: AIM ImmunoTech CEO Acquires 312,500 Shares at $0.32
SEC Form 4 Filing
Thomas K. Equels, CEO and President of AIM ImmunoTech Inc., acquired 312,500 shares of common stock at a price of $0.32 per share on September 11, 2024.
Summary
- On September 11, 2024, Thomas K. Equels, the CEO and President of AIM ImmunoTech Inc., acquired 312,500 shares of the company's common stock.
- The shares were purchased at a price of $0.32 per share.
- Following the transaction, Equels directly owns 1,468,042 shares of AIM ImmunoTech Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is generally seen as a positive sign, but without more context, it's difficult to gauge the overall impact.
Positives
- The CEO's purchase of shares may signal confidence in the company's future prospects.
Industry Context
Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's valuation and future performance. This purchase could be interpreted as a positive signal.
Stakeholder Impact
- Shareholders may view the CEO's stock purchase as a positive indicator of the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 09/11/2024 | Date of the stock acquisition by Thomas K. Equels |
| 09/12/2024 | Date of signature on the Form 4 filing |
Keywords
AIM ImmunoTech Inc., Thomas K. Equels, stock acquisition, Form 4, insider trading, common stock, ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.